We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.91B
AUM Growth
-$2.06B
Cap. Flow
+$62M
Cap. Flow %
0.63%
Top 10 Hldgs %
40.04%
Holding
153
New
17
Increased
26
Reduced
29
Closed
21

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$123M
2
WMGI
Wright Medical Group Inc
WMGI
+$120M
3
LLY icon
Eli Lilly
LLY
+$107M
4
HCA icon
HCA Healthcare
HCA
+$72.7M
5
DVAX
Dynavax Technologies
DVAX
+$70M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$161M
2
SHPG
Shire pic
SHPG
+$153M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$120M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$119M
5
GILD icon
Gilead Sciences
GILD
+$79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Financials 0.24%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
51
Medtronic
MDT
$112B
$39.4M 0.4%
588,299
-58,001
-9% -$4.27M
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
$39M 0.39%
1,021,600
– –
LOXO
53
DELISTED
Loxo Oncology, Inc
LOXO
$38M 0.38%
2,175,857
– –
INFI
54
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$37.3M 0.38%
4,416,300
– –
ACHN
55
DELISTED
Achillion Pharmaceuticals
ACHN
$36.1M 0.36%
+5,222,500
New +$42.5M
IMGN
56
DELISTED
Immunogen Inc
IMGN
$34.5M 0.35%
3,594,000
+2,564,000
+249% +$37.5M
GWPH
57
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$34.5M 0.35%
377,100
+52,100
+16% +$5.79M
EXAS
58
DELISTED
Exact Sciences
EXAS
$32M 0.32%
1,778,000
– –
SIEN
59
DELISTED
Sientra, Inc.
SIEN
$30.2M 0.31%
298,000
-20,531
-6% -$4.66M
CERS icon
60
Cerus
CERS
$585M
$29.5M 0.3%
6,504,400
-1,803,327
-22% -$9.33M
BHC icon
61
Bausch Health
BHC
$1.68B
$29.4M 0.3%
165,000
– –
AFMD
62
DELISTED
Affimed
AFMD
$28.3M 0.29%
458,262
-123,201
-21% -$15.3M
UNH icon
63
UnitedHealth
UNH
$387B
$27.6M 0.28%
238,000
– –
JNJ icon
64
Johnson & Johnson
JNJ
$644B
$27.3M 0.28%
292,000
-325,000
-53% -$31.4M
PRQR icon
65
ProQR Therapeutics
PRQR
$246M
$26.8M 0.27%
1,841,400
+10,000
+0.5% +$167K
LUMO
66
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$25.5M 0.26%
+79,145
New +$34.8M
FWP
67
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$22.6M 0.23%
137,229
– –
DYAX
68
DELISTED
DYAX CORPORATION
DYAX
$21.3M 0.22%
1,117,000
– –
LKFT
69
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$20.9M 0.21%
512,900
– –
KDNY
70
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$20.6M 0.21%
213,104
– –
MRK icon
71
Merck
MRK
$324B
$20.5M 0.21%
434,920
– –
XNPT
72
DELISTED
XENOPORT, INC.
XNPT
$20M 0.2%
5,768,400
– –
ZBH icon
73
Zimmer Biomet
ZBH
$18.7B
$19.9M 0.2%
218,669
– –
LAB icon
74
Standard BioTools
LAB
$318M
$19.9M 0.2%
2,449,900
– –
BMRN icon
75
BioMarin Pharmaceuticals
BMRN
$12B
$19.8M 0.2%
188,000
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2015 Portfolio in Review

As of Q3 2015, OrbiMed held 153 positions worth $9.91B, down 17% from $12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2015 filing shows 17 new, 26 increased, 29 reduced and 21 closed positions. Its largest new stake was Eli Lilly: 1,272,000 shares worth $106M. The largest sale was MEDIVATION, INC., an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2015 buy was Eli Lilly: 1,272,000 shares worth $106M.
  • OrbiMed added most to Teva Pharmaceuticals in Q3 2015, an estimated $123M increase.
  • OrbiMed's biggest Q3 2015 reduction was Shire pic, cutting an estimated $153M.
  • OrbiMed fully exited MEDIVATION, INC. in Q3 2015, selling an estimated $161M.
  • OrbiMed's ten largest holdings make up 40% of its $9.91B portfolio in Q3 2015.
  • OrbiMed opened 17 new positions and closed 21 in Q3 2015.
  • OrbiMed's portfolio value fell 17% quarter-over-quarter to $9.91B.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.